Monitor upcoming Phase 2 IND filing for Lucid-MS in H1 2026 and Unbuzzd's progress toward IPO and $5M raise, which could generate non-dilutive cash flow. The 50% reduction in payables and sustained cash runway are positive signs, but lack of revenue growth or profitability remains a concern.
Price Chart
Executive Summary
Quantum BioPharma reported its 2025 financial results, highlighting a reduction in operating expenses to $15.3M from $16.1M in 2024, improved working capital with $11.3M in cash and digital assets, and progress in its drug development pipeline, including completion of Phase 1 toxicity studies for its multiple sclerosis candidate Lucid-MS. The company also announced a peer-reviewed publication of positive results for its alcohol metabolism product unbuzzd and secured a Health Canada license for Qlarity, while Unbuzzd launched a $5M Reg D offering ahead of a potential IPO.
Key Financial Metrics
Key Facts
- Operating expenses decreased to $15.3M in 2025 from $16.1M in 2024 (5% reduction)
- Cash and fair market value of digital assets: $11.3M as of filing
- Trade and other payables reduced by 50% to $2.0M
- R&D expenses dropped to $2.8M from $6.1M due to completion of Phase 1 trials and Australian tax credits
- General and administrative expenses decreased to $9.0M from $9.4M
- Health Canada granted product license for Qlarity, allowing Canadian sales
- Unbuzzd launched $5.0M Reg D 506(c) offering and hired MNP for IPO preparation
- Lucid-MS completed 3- and 6-month oral toxicity studies with no significant side effects; IND filing for Phase 2 expected in H1 2026
- First MS patient scanned in joint study with Massachusetts General Hospital using novel PET imaging technique
- Quantum holds 19.84% equity in Unbuzzd as of December 31, 2025, with 7% royalty on sales until $250M is reached
Financial Impact
Operating expenses down $800K YoY; R&D costs down $3.3M due to trial completion and tax incentives; $11.3M in liquid resources supports operations into 2028
Risk Factors
- No revenue generation disclosed; company remains pre-revenue with reliance on capital markets
- Forward-looking statements dominate narrative with no near-term commercial products
- Legal risk from ongoing lawsuit against CIBC and RBC with uncertain outcome
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263740 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.11 | awaiting T+20 | — | $2.17 (−30.23%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.17 (−29.77%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.17 (−29.77%) |
Oct 5, 2026 22d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.17 (−33.64%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.17 (−45.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.17 (−41.67%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.17 (−41.67%) |
Sep 15, 2026 6w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.17 (−37.28%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.17 (−29.55%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.17 (−29.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers